Merrimack Pharmaceuticals (NasdaqGM:MACK) - Share price, News & Analysis

MACK fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

MACK Stock Overview

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company.

Rewards

Earnings have grown 61.9% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Does not have a meaningful market cap ($68M)

Merrimack Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Merrimack Pharmaceuticals
Historical stock prices
Current Share Price	US$5.25
52 Week High	US$7.41
52 Week Low	US$3.66
Beta	1.65
1 Month Change	-12.06%
3 Month Change	-15.32%
1 Year Change	-18.61%
3 Year Change	-16.00%
5 Year Change	-84.56%
Change since IPO	-91.31%

Recent News & Updates

Mar 19

Here's Why We're Not At All Concerned With Merrimack Pharmaceuticals' (NASDAQ:MACK) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

May 19

We're Interested To See How Merrimack Pharmaceuticals (NASDAQ:MACK) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

	MACK	US Biotechs	US Market
7D	1.0%	3.6%	0.1%
1Y	-18.6%	-22.1%	-12.7%

Return vs Industry: MACK exceeded the US Biotechs industry which returned -21.4% over the past year.

Return vs Market: MACK underperformed the US Market which returned -11.5% over the past year.

Price Volatility

Is MACK's price volatile compared to industry and market?
MACK volatility
MACK Average Weekly Movement	8.1%
Biotechs Industry Average Movement	12.4%
Market Average Movement	8.0%
10% most volatile stocks in US Market	17.0%
10% least volatile stocks in US Market	3.0%

Stable Share Price: MACK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: MACK's weekly volatility (8%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1993	n/a	Gary Crocker	https://www.merrimack.com

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

Merrimack Pharmaceuticals Fundamentals Summary

How do Merrimack Pharmaceuticals's earnings and revenue compare to its market cap?
MACK fundamental statistics
Market Cap	US$67.72m
Earnings (TTM)	-US$1.89m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-37.2x

P/E Ratio

Is MACK overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MACK income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$1.89m
Earnings	-US$1.89m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)	-0.14
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did MACK perform over the long term?

See historical performance and comparison

Valuation

Is Merrimack Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MACK's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MACK's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: MACK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: MACK is unprofitable, so we can't compare its PE Ratio to the US market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MACK's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MACK is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (1.5x).

Future Growth

How is Merrimack Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

10.9%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Merrimack Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Merrimack Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

61.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MACK is currently unprofitable.

Growing Profit Margin: MACK is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MACK is unprofitable, but has reduced losses over the past 5 years at a rate of 61.9% per year.

Accelerating Growth: Unable to compare MACK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MACK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).

Return on Equity

High ROE: MACK has a negative Return on Equity (-13.44%), as it is currently unprofitable.

Financial Health

How is Merrimack Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MACK's short term assets ($14.6M) exceed its short term liabilities ($564.0K).

Long Term Liabilities: MACK has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: MACK is debt free.

Reducing Debt: MACK currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable MACK has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: MACK is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 46.9% per year.

Dividend

What is Merrimack Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MACK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MACK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MACK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MACK's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MACK has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

5.4yrs

Average management tenure

CEO

Gary Crocker (69 yo)

5.58yrs

Tenure

US$105,437

Compensation

Mr. Gary L. Crocker, MBA, has been President (Principal Executive Officer) and Treasurer (Principal Financial and Accounting Officer) of Merrimack Pharmaceuticals, Inc. since June 28, 2019. He is Chief Exe...

CEO Compensation Analysis

Compensation vs Market: Gary's total compensation ($USD105.44K) is below average for companies of similar size in the US market ($USD770.27K).

Compensation vs Earnings: Gary's compensation has increased whilst the company is unprofitable.

Leadership Team

Experienced Management: MACK's management team is seasoned and experienced (5.4 years average tenure).

Board Members

Experienced Board: MACK's board of directors are considered experienced (4.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: MACK insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/19 00:00
End of Day Share Price	2022/05/19 00:00
Earnings	2022/03/31
Annual Earnings	2021/12/31